The relationship between metabolic syndrome (MS) and prostate cancer (PCA) is highly complex and harbors multiple facets not least because MS is not a single entity but represents a poorly defined inhomogeneous mixture of different diseases and conditions.
Although numerous studies suggest a correlation between MS or components of MS and the development of prostate cancer, current evidence cannot be considered convincing. While diabetes appears to be inversely related to PCA, increased serum levels of triglycerides, cholesterol and insulin-like growth factor 1 (IGF-1) may be predictive for high grade disease. Further studies suggested that MS and high serum insulin levels are independent predictors of an unfavorable prognosis in patients with metastatic PCA. Early detection and improved therapeutic options have dramatically prolonged the course of the disease in advanced PCA through the last decades. As a consequence, development of MS in patients undergoing hormone therapy along with the cardiovascular risks has gained increasing relevance. Based on this evolution prevention, early detection and sustainable therapy represent an important clinical challenge to modern urologists active in urooncology.
Written by:
Schmitz-Dräger BJ, Lümmen G, Bismarck E, Fischer C. Are you the author?
Urologie, EuromedClinic, Europa-Allee 1, 90763, Fürth, Deutschland.
Reference: Urologe A. 2013 Mar 15. Epub ahead of print.
doi: 10.1007/s00120-013-3135-3
PubMed Abstract
PMID: 23494337
Article in German.
UroToday.com Prostate Cancer Section
